Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
Neuraxpharm has struck a deal to acquire Buccolam (midazolam), “the only buccal midazolam approved across Europe,” from Takeda in a move that the central nervous system specialist says will strengthen its position in several European countries while also offering the opportunity to expand its footprint into markets such as the Nordics and Ireland.
The deal for Buccolam – used for the emergency treatment of epileptic children – gives Neuraxpharm global rights to the...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
